Cardiol Therapeutics Class Stock Alpha and Beta Analysis

CRDL Stock  CAD 2.26  0.05  2.16%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cardiol Therapeutics Class. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cardiol Therapeutics over a specified time horizon. Remember, high Cardiol Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cardiol Therapeutics' market risk premium analysis include:
Beta
1.26
Alpha
(0.30)
Risk
3.9
Sharpe Ratio
(0.03)
Expected Return
(0.13)
Please note that although Cardiol Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Cardiol Therapeutics did 0.30  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Cardiol Therapeutics Class stock's relative risk over its benchmark. Cardiol Therapeutics has a beta of 1.26  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiol Therapeutics will likely underperform. At this time, Cardiol Therapeutics' Book Value Per Share is very stable compared to the past year. As of the 1st of December 2024, Tangible Book Value Per Share is likely to grow to 0.63, while Enterprise Value Over EBITDA is likely to drop (1.36).

Cardiol Therapeutics Quarterly Cash And Equivalents

44.94 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Cardiol Therapeutics Backtesting, Cardiol Therapeutics Valuation, Cardiol Therapeutics Correlation, Cardiol Therapeutics Hype Analysis, Cardiol Therapeutics Volatility, Cardiol Therapeutics History and analyze Cardiol Therapeutics Performance.

Cardiol Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cardiol Therapeutics market risk premium is the additional return an investor will receive from holding Cardiol Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cardiol Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cardiol Therapeutics' performance over market.
α-0.3   β1.26

Cardiol Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cardiol Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Cardiol Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Cardiol Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Cardiol Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cardiol Therapeutics shares will generate the highest return on investment. By understating and applying Cardiol Therapeutics stock market price indicators, traders can identify Cardiol Therapeutics position entry and exit signals to maximize returns.

Cardiol Therapeutics Return and Market Media

The median price of Cardiol Therapeutics for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 is 2.64 with a coefficient of variation of 9.67. The daily time series for the period is distributed with a sample standard deviation of 0.26, arithmetic mean of 2.65, and mean deviation of 0.18. The Stock received some media coverage during the period.
 Price Growth (%)  
       Timeline  
1
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares CRDL Stock News - StockTitan
10/09/2024
2
Cardiol Therapeutics Faces Rising Losses and Falling Assets - TipRanks
11/14/2024
3
Cardiol Therapeutics Shares Up 1.8 percent - Whats Next - MarketBeat
11/22/2024

About Cardiol Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cardiol or other stocks. Alpha measures the amount that position in Cardiol Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Days Sales Outstanding1.7K1.5K
PTB Ratio2.512.38
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cardiol Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cardiol Therapeutics' short interest history, or implied volatility extrapolated from Cardiol Therapeutics options trading.

Build Portfolio with Cardiol Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Cardiol Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Cardiol Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Cardiol Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...